Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE |
SEBI has approved the Initial Public Offer (IPO) of Molbio Diagnostics Ltd. on December 1, 2025. The company will proceed with next steps to launch the Initial Public Offer (IPO) subject to market conditions and other approvals. The SEBI approval is valid for 12 months.
Molbio Diagnostics Ltd. IPO is a Book Build Issue consisting of fresh issue of ₹200.00 crores and an offer for sale (OFS) of upto 1.26 crore equity shares.
The equity shares are proposed to be listed on NSE and BSE. Kotak Mahindra Capital Co.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Molbio Diagnostics IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Fresh Issue | [.] shares (agg. up to ₹200 Cr) |
| Offer for Sale | 1,25,56,000 shares of ₹1 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 11,27,59,750 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Fri, Aug 22, 2025 |
| SEBI/Exchange approval received | Mon, Dec 1, 2025 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Offer |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care (“POC”) diagnostics company focused on delivering accurate, rapid, and cost-effective healthcare technologies for infectious and non-communicable diseases.
The company has developed the ‘Truenat’ platform, a portable polymerase chain reaction (“PCR”) system that provides decentralized diagnosis within an hour, even in resource-limited settings. As of March 31, 2025, the platform is patented in over 100 countries and offers molecular testing for 30 diseases, including tuberculosis (TB), COVID, Hepatitis B and C, HIV, and HPV through 42 assays. The ‘Truenat’ TB test is one of only two WHO-endorsed rapid molecular tests for initial TB diagnosis and rifampicin resistance detection.
The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiary Prognosys, associate OptraScan, and collaboration partner UE Lifesciences.
The company operates five manufacturing facilities in India – two in Goa, one in Visakhapatnam (Andhra Pradesh), and two in Bengaluru (Karnataka). These units manufacture diagnostic devices, test kits, and radiology products such as ultraportable and mobile X-ray systems.
The company has a global presence in over 80 countries with 33 international distributors and has sold more than 10,000 devices as of March 31, 2025. Products are supplied directly and through distributors to public health programs, diagnostic laboratories, and hospitals.
The company generates revenues from device sales as well as recurring revenues from proprietary test kits.
As of March 31, 2025, the company employed 1,000 permanent employees and 1,511 contract labourers.
Molbio Diagnostics Ltd.'s revenue increased by 22% and profit after tax (PAT) rose by 66% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 1,034.21 | 1,221.06 | 1,461.56 |
| Total Income | 1,027.94 | 840.66 | 337.41 |
| Profit After Tax | 138.58 | 83.54 | -3.45 |
| EBITDA | 256.64 | 185.09 | 48.11 |
| NET Worth | 952.95 | 807.94 | 706.04 |
| Total Borrowing | 123.16 | 174.58 | 108.44 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space. | 118.08 |
| 2 | Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and | 79.04 |
| 3 | General corporate purposes |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 16.20% |
| ROCE | 20.98% |
| RoNW | 15.23% |
| PAT Margin | 13.48% |
| EBITDA Margin | 24.97% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 12.29 | |
| Promoter Holding | 46.65% |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLMs | |
| 2 | Brokerage, selling commission, bidding charges, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs, sponsor bank(s) | |
| 3 | Fees payable to Registrar to the Offer | |
| 4 | Printing and stationery expenses | |
| 5 | Advertising and marketing expenses | |
| 6 | Listing fees, SEBI fees, BSE and NSE processing fees, book-building software fees, and other regulatory expenses | |
| 7 | Other regulatory expenses | |
| 8 | Fees payable to the advisors and other parties to the Offer namely legal counsels, auditors, independent chartered accountant, independent chartered engineer, IPR consultant, Project Report Provider, practicing company secretary and others | |
| 9 | Miscellaneous |
Lead Manager Reports
Molbio Diagnostics IPO is a main-board IPO of 0 equity shares of the face value of ₹1 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Molbio Diagnostics IPO open and close dates are not available as of now.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Molbio Diagnostics IPO using UPI as a payment gateway. Zerodha customers can apply in Molbio Diagnostics IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Molbio Diagnostics IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Molbio Diagnostics IPO dates are not announced. Please check back again after some time.
Molbio Diagnostics IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Molbio Diagnostics IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Molbio Diagnostics IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Molbio Diagnostics IPO allotment status.
The Molbio Diagnostics IPO listing date is not yet announced. The tentative date of listing is .
